文献速递儿科影像技术与安全US

儿童超声造影安全性综述

Contrast-enhanced ultrasound: a comprehensive review of safety in children.
PubMed 文献 · Pediatr Radiol · 2021-10-30

本文综述了儿童超声造影(CEUS)的安全性文献,涉及静脉、膀胱内及其他腔道应用。截至2021年8月,静脉CEUS严重不良事件发生率为0.22%(10/4518例儿童),非严重不良事件为1.20%;膀胱内应用非严重不良事件为0.31%(38/12362例),多归因于导尿。整体安全性良好。

要点

  • 儿童静脉CEUS严重不良事件罕见,总体发生率约0.22%。
  • 膀胱内超声造影不良事件多与导尿相关,而非造影剂本身。
  • Lumason已获FDA批准用于儿童局灶性肝病变、超声心动图和膀胱输尿管反流。

核心结论

  • 儿童CEUS在静脉、膀胱内及腔道应用中安全性良好,严重不良事件罕见。

研究设计与样本

  • 综述性研究,汇总截至2021年8月的儿童CEUS文献。
  • 静脉CEUS纳入57项儿童原创研究,共4518例儿童、4906次检查。
  • 膀胱内CEUS纳入31项研究,共12362例儿童。
  • 参考标准为已发表的安全性数据及FDA批准信息。

诊断标准与关键数值

  • 静脉CEUS严重不良事件发生率:0.22%(10/4518儿童)和0.20%(10/4906次检查)。
  • 静脉CEUS非严重不良事件发生率:1.20%(54/4518儿童)和1.10%(54/4906次检查)。
  • 膀胱内CEUS非严重不良事件发生率:0.31%(38/12362儿童),多归因于导尿。

临床应用与阅片要点

  • 儿童CEUS可安全用于静脉、膀胱内及腔道适应症,严重过敏反应极罕见。
  • 膀胱内造影后不良事件需鉴别导尿相关并发症。

局限性

  • 为综述性分析,依赖已发表文献,可能存在发表偏倚。
  • 部分应用(如腔道、淋巴内)安全性数据仍在积累中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Contrast-enhanced ultrasound (CEUS) has been increasingly used in pediatric radiology practice worldwide. For nearly two decades, CEUS applications have been performed with the off-label use of gas-containing second-generation ultrasound contrast agents (UCAs). Since 2016, the United States Food and Drug Administration (FDA) has approved the UCA Lumason for three pediatric indications: the evaluation of focal liver lesions and echocardiography via intravenous administration and the assessment of vesicoureteral reflux via intravesical application (contrast-enhanced voiding urosonography, ceVUS). Prior to the FDA approval of Lumason, numerous studies with the use of second-generation UCAs had been conducted in adults and children. Comprehensive protocols for clinical safety evaluations have demonstrated the highly favorable safety profile of UCA for intravenous, intravesical and other intracavitary uses. The safety data on CEUS continue to accumulate as this imaging modality is increasingly utilized in clinical settings worldwide. As of August 2021, 57 pediatric-only original research studies encompassing a total of 4,518 children with 4,906 intravenous CEUS examinations had been published. As in adults, there were a few adverse events; the majority of these were non-serious, although very rarely serious anaphylactic reactions were reported. In the published pediatric-only intravenous CEUS studies included in our analysis, the overall incidence rate of serious adverse events was 0.22% (10/4,518) of children and 0.20% (10/4,906) of all CEUS examinations. Non-serious adverse events from the intravenous CEUS were observed in 1.20% (54/4,518) of children and 1.10% (54/4,906) of CEUS examinations. During the same time period, 31 studies with the intravesical use of UCA were conducted in 12,362 children. A few non-serious adverse events were encountered (0.31%; 38/12,362), but these were most likely attributable to the bladder catheterization rather than the UCA. Other developing clinical applications of UCA in children, including intracavitary and intralymphatic, are ongoing. To date, no serious adverse events have been reported with these applications. This article reviews the existing pediatric CEUS literature and provides an overview of safety-related information reported from UCA uses in children.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Ntoulia A, Anupindi SA, Back SJ, et al. Contrast-enhanced ultrasound: a comprehensive review of safety in children. Pediatr Radiol. 2021. PMID: 34716453. doi:10.1007/s00247-021-05223-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。